|Mr. Philip A. Serlin CPA, MBA||Chief Exec. Officer||489k||N/A||1960|
|Ms. Mali Zeevi CPA||Chief Financial Officer||N/A||N/A||1976|
|Dr. Ella Sorani||VP R&D||280k||N/A||1968|
|Dr. Abi Vainstein-Haras||VP of Clinical Devel.||302k||N/A||1975|
|Advocate Norman Kotler||Internal Enforcement Officer, Gen. Counsel and Corp. Sec.||N/A||N/A||1952|
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates for pre-clinical projects of BL-1220 and BL-1230; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is based in Modi'in, Israel.
BioLineRx Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.